All of the safeguards incorporated within parts 50, 56, 312, 314, and 600 of this chapter designed to ensure the safety of clinical testing and the safety of products following marketing approval apply to drugs covered by this section. This includes the requirements for informed consent ( part 50 of this chapter) and institutional review boards ( part 56 of this chapter ). These safeguards further include the review of animal studies prior to initial human testing ( § 312.23 ), and the monitoring of adverse drug experiences through the requirements of IND safety reports ( § 312.32 ), safety update reports during agency review of a marketing application ( § 314.50 of this chapter ), and postmarketing adverse reaction reporting ( § 314.80 of this chapter ).
Title 21 published on 2012-04-01
The following are only the Rules published in the Federal Register after the published date of Title 21.
For a complete list of all Rules, Proposed Rules, and Notices view the Rulemaking tab.
This is a list of United States Code sections, Statutes at Large, Public Laws, and Presidential Documents, which provide rulemaking authority for this CFR Part.